Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent AT-III Infusion After Liver Transplantation
NCT04219579Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of antithrombin III in thrombosis (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Proportion of patients within target range at postoperative 72 hours. Started Jan 2020; status: completed.
02
Drugs
antithrombin III
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04219579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04219579.